01—Abstract
Summary
Summary of the 8-K filed July 16, 2025. Cited figures are marked; the original filing is the authoritative source.
Johnson & Johnson reported second-quarter 2025 results on July 16, 2025, with reported sales of $23.7 billiona, up 5.8% year over year, and operational growth of 4.6%.
Adjusted operational growth, which excludes acquisitions, divestitures and currency, was a more modest 3.0%b. U.S. sales grew 7.8% while international sales rose only 3.2% (0.6% operational). Growth was led by MedTech, up 7.3% reported, and Innovative Medicine, up 4.9%.
Within Innovative Medicine, STELARA's steep erosion (about 1,170 basis points of drag) was offset by growth in DARZALEX, CARVYKTI, TREMFYA and others. Reported GAAP EPS was $2.29c, up 18.7%, while adjusted EPS was $2.77, down 1.8% from $2.82, with adjusted net earnings down 2.1%. The GAAP-to-adjusted gap was driven largely by $1.27 billion in intangible amortization and $246 million in acquisition-related costs.
Management raised full-year 2025 guidance. Estimated reported sales growth at the midpoint rose to 5.4% (about $93.4 billiond), and adjusted operational EPS guidance rose to $10.68 at the midpoint. Reported EPS guidance rose $0.25 to a midpoint of $10.85, though much of the increase reflects favorable foreign exchange and the timing of the Shockwave and Intra-Cellular acquisitions rather than purely operating momentum.
Management guided to the operational sales midpoint rising to 4.8%, from 3.8% previously. Adjusted operational sales growth guidance rose to 3.5% from 2.5%. Management described an expected elevated second-half growth profile tied to pending approvals and submissions across oncology, depression, psoriasis, surgery and cardiovascular.
The release also notes Q2 free cash flow of roughly $6.2 billion versus $7.5 billion a year earlier, a decline investors should monitor. Filing-level items are limited to routine disclosures: an earnings release furnished under Item 2.02 with exhibits 99.1 and 99.2, and the cover page in Inline XBRL. No material agreements, leadership changes requiring 8-K disclosure, or legal settlements are announced in the filing itself.
The press release does note Daniel Pinto's election to the board. Investors should focus on the sharp deceleration in underlying growth ex-acquisitions, the STELARA biosimilar erosion, and whether the second-half acceleration materializes.
02—Key points
Key Highlights
- Reported Q2 2025 sales rose 5.8% to $23.7 billion, with operational growth of 4.6% and adjusted operational growth of only 3.0%.
- GAAP diluted EPS was $2.29, up 18.7% year over year, while adjusted EPS was $2.77, down 1.8% from $2.82.
- Full-year 2025 reported sales guidance was raised to a midpoint of 5.4% growth (about $93.4 billion), and adjusted operational EPS guidance rose to $10.68.
- Full-year reported EPS guidance was raised $0.25 to a $10.85 midpoint; adjusted operational EPS midpoint rose to $10.68.
- STELARA sales fell 42.7% in Q2 (about 1,170 basis points of drag on Innovative Medicine), signaling continued biosimilar erosion.
- MedTech grew 7.3% reported and 6.1% operationally, led by electrophysiology, Abiomed and Shockwave, while Innovative Medicine grew 4.9% reported.
- Q2 free cash flow was roughly $6.2 billion versus $7.5 billion a year earlier, a notable year-over-year decline.
03—Questions
Frequently Asked Questions
Why is reported sales growth (5.8%) so much higher than adjusted operational growth (3.0%)?
The gap reflects two items. Currency contributed about 1.2 percentage points of favorable translation. Acquisitions, mainly Intra-Cellular Therapies (CAPLYTA) and Shockwave Medical, contributed roughly 2.4 percentage points net of divestitures. Stripping out both leaves underlying growth of 3.0%, which is the more relevant figure for assessing organic demand.
Why did GAAP EPS rise 18.7% while adjusted EPS fell 1.8%?
Adjusted EPS excludes intangible amortization ($1.27 billion pre-tax in Q2 2025, up from $1.11 billion), acquisition and integration costs ($246 million), litigation and other special items. Amortization growth from acquisitions reduces adjusted comparisons less than GAAP, but the GAAP increase was helped by lower net other expense and a lower effective tax rate (14.7% versus 18.5%), while the adjusted tax rate rose to 18.2%.
What drove the raised full-year guidance?
Management attributed the guidance increase to strong operational performance and favorable foreign exchange, with reported sales midpoint raised by about $2 billion. Adjusted operational sales growth midpoint rose from 2.5% to 3.5%, indicating genuine improvement. Investors should note that part of the reported EPS increase reflects currency and acquisition timing rather than purely operating momentum.
How serious is the STELARA decline for the company's outlook?
STELARA sales fell 42.7% to $1.65 billion in Q2 and are on a steep downward path as biosimilars compete. The drag was about 1,170 basis points on Innovative Medicine growth. Growth in DARZALEX, CARVYKTI, TREMFYA and oncology products has so far offset this erosion, but continued STELARA losses are a key risk to sustaining growth in the second half.
Is there anything in this 8-K that signals a material corporate event?
No. The 8-K is a routine Item 2.02 filing furnishing the Q2 2025 earnings release and supplementary data. It does not announce a major transaction, litigation resolution or executive change requiring separate disclosure. The press release does note the board election of Daniel Pinto, President of JPMorganChase, and the regulatory approvals and submissions listed are the principal pipeline catalysts to monitor.
04—Continue